Addendum
Ozanimod (multiple sclerosis) - Addendum to Commission A20-59
Report documents
-
Addendum
Ozanimod (multiple sclerosis) - Addendum to Commission A20-59
Dossier assessment
Indication:
| Adults with relapsing remitting multiple sclerosis (RRMS) |
Result of dossier assessment:
| Treatment-naive patients or patients whose RRMS is not highly active under disease-modifying therapy: unchanged (proof of considerable added benefit). Highly active RRMS despite therapy for which switch within the basic therapy is an option: now proof of major added benefit for men; for women: proof of considerable added benefit. |
Additional information
Federal Joint Committee (G-BA)
07.01.2021 A G-BA decision was published.
Project details
- Project no.
- A20-96
- Commission
- Commission awarded on 25.11.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed